• Mesoblast Ltd., of Melbourne, Australia, received about $4.3 million under the Australian government's Innovation Australia Research and Development Tax Incentive Program. The funds will be used to advance development of Mesoblast's mesenchymal precursor cell technology platform and product pipeline.